A study published in the New England Journal of Medicine provides molecular evidence of multiorgan damage in patients with immune-related adverse events (irAEs) after treatment with immune checkpoint inhibitors. They analyzed more than 15,000 patients from one database and more than 50,000 from the other, identifying seven main groups of irAEs according to affected organs: endocrine, skin, respiratory, gastrointestinal, hepatic, musculoskeletal, and neurological. Multiple concurrent irAEs were common and had varying impacts on patient survival. For example, patients with concomitant endocrine or cutaneous irAEs had better survival, whereas neurologic irAEs were associated with worse survival. The average follow-up of patients was approximately 8 to 10 months. These results were also confirmed in an independent cohort, which emphasizes the importance of monitoring multiple organs during treatment with immune therapy. The study thus provides important molecular and clinical evidence of the complexity and severity of multiorgan immune responses in these patients[1].